Microangiopathic hemolytic anemia, often shortened to MAHA, is a type of anemia caused by red blood cells being physically torn apart as they pass through damaged or clot-clogged small blood vessels. The destruction leaves behind distinctive cell fragments called schistocytes, visible on a blood smear, that serve as the hallmark clue for diagnosis. MAHA is not a disease in itself but a laboratory finding that points toward a group of serious underlying conditions, and figuring out which one is driving it can be the difference between a targeted cure and a fatal delay.
How Red Blood Cells Get Shredded
In healthy circulation, red blood cells glide through tiny capillaries without trouble. In MAHA, something has gone wrong with the inner lining of those small vessels. Damage to the endothelium triggers clot formation inside the microvasculature, and strands of fibrin stretch across the narrowed channels like tripwires. Red blood cells slam into these strands at speed, and the mechanical force literally slices them into fragments.1PubMed. Diagnostic approach to microangiopathic hemolytic disorders Those fragments, the schistocytes, spill into the bloodstream along with the contents of ruptured cells. Platelets get consumed in the process of forming all those tiny clots, so platelet counts drop at the same time red cells are being destroyed.
This combination of red cell destruction and platelet consumption is what doctors call thrombotic microangiopathy, or TMA. MAHA is the anemia side of TMA. Every condition that causes TMA produces MAHA, but MAHA can also show up in a few situations where widespread microvascular clotting is the mechanism without fitting neatly into a single TMA diagnosis.2American Society of Hematology. Where have all the platelets gone? HIT, DIC, or something else?
What Shows Up in the Lab
When a clinician suspects MAHA, a handful of lab results tend to cluster together. Haptoglobin, a protein that mops up free hemoglobin released from broken red cells, drops to very low levels. Lactate dehydrogenase (LDH), an enzyme that leaks out of damaged cells, shoots up. A blood count shows anemia and low platelets, and the reticulocyte count rises because the bone marrow is scrambling to replace lost red cells.3PubMed Central. Microangiopathic Anemia
The single most important test is looking at the blood smear under a microscope. Schistocytes, those jagged red cell fragments, confirm that the destruction is mechanical rather than caused by antibodies or other processes. The direct antiglobulin test (sometimes called the Coombs test) is typically negative in MAHA, which helps distinguish it from autoimmune hemolytic anemia, where antibodies are attacking the red cells instead.4PubMed Central. Microangiopathic Anemia A positive Coombs test points the investigation in a different direction entirely.
Coagulation studies also matter. In classic TMA subtypes like thrombotic thrombocytopenic purpura (TTP), the standard clotting tests tend to stay relatively normal. In disseminated intravascular coagulation (DIC), by contrast, clotting times are prolonged and fibrinogen drops, because the entire clotting cascade has been activated system-wide. That distinction, normal coagulation panel versus deranged coagulation panel, is one of the first branch points when a doctor sees MAHA on a blood smear.
Thrombotic Thrombocytopenic Purpura
TTP is one of the most feared causes of MAHA because it can kill rapidly without treatment, yet responds well once the right therapy starts. The underlying problem is a shortage of ADAMTS13, an enzyme that normally clips unusually large von Willebrand factor multimers into smaller, less sticky pieces. When ADAMTS13 activity falls below about ten percent of normal, those oversized multimers accumulate and cause platelets to clump inside small vessels throughout the body, particularly in the brain and kidneys.5PubMed Central. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura
Most cases of TTP are acquired, meaning the immune system produces autoantibodies that knock out ADAMTS13. A much smaller number are hereditary, caused by mutations in the ADAMTS13 gene itself. The disease was first recognized in 1924 and for decades was almost universally fatal; the discovery of ADAMTS13 deficiency as the driving risk factor in 1997 transformed understanding and treatment.6PubMed. Thrombotic thrombocytopenic purpura
Because ADAMTS13 results take time to come back from the lab, clinicians often need to make treatment decisions before the enzyme level is known. The PLASMIC score was developed for exactly this purpose. It uses seven readily available clinical parameters, including platelet count, signs of hemolysis, absence of active cancer, absence of a prior transplant, mean red cell volume, clotting time, and kidney function, to predict the likelihood of severe ADAMTS13 deficiency.7PubMed. Validation of PLASMIC score: an academic medical center case series (2012-present) A high score essentially tells the team to start plasma exchange immediately rather than waiting for the enzyme assay.8PubMed Central. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment
Treating TTP and the Role of Caplacizumab
Plasma exchange has been the backbone of TTP treatment for decades. It works two ways: it removes the autoantibodies attacking ADAMTS13 and it replaces the missing enzyme with fresh donor plasma. Immunosuppression, typically with corticosteroids and rituximab, targets the immune system to shut down antibody production.
More recently, caplacizumab has changed the landscape. This drug blocks the interaction between von Willebrand factor and platelets, essentially preventing the pathological clumping while the immune therapy takes effect. In a major trial, patients who received caplacizumab had a roughly 74 percent lower rate of a composite of TTP-related death, recurrence, or major thromboembolic events compared to placebo. Recurrences of TTP during the trial dropped by about 67 percent, and no patients in the caplacizumab group developed refractory disease, compared to three in the placebo group.9PubMed. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura The drug does increase bleeding risk since it interferes with normal platelet adhesion, so its use requires balancing speed of platelet recovery against that trade-off.
Hemolytic Uremic Syndrome
HUS is the other major TMA that produces MAHA, and it comes in two fundamentally different flavors that require completely different management.
Shiga Toxin-Associated HUS
The classic form, most common in young children, is triggered by infection with bacteria that produce Shiga toxin, especially certain strains of E. coli. The toxin invades endothelial cells lining blood vessels in the kidneys, triggering massive cell death and activating clotting within the renal capillaries. The result is the triad of MAHA, low platelets, and acute kidney injury.10PubMed Central. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review Treatment is mainly supportive, with fluids, dialysis if kidneys fail, and careful monitoring. Antibiotics are generally avoided during the acute diarrheal illness because they can increase toxin release and worsen the syndrome. Most children recover kidney function, though a subset develop lasting damage.
Complement-Mediated HUS
Atypical HUS, now more precisely called complement-mediated HUS, is a different beast. Here the problem is runaway activation of the complement system, a branch of the immune system that normally helps clear pathogens. Mutations in genes that regulate the alternative complement pathway, including factor H, factor I, membrane cofactor protein, and several others, leave the system unable to rein itself in.11PubMed Central. Genetics and complement in atypical HUS12PubMed. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome The overactive complement cascade damages endothelial cells, triggering clotting and organ injury, especially in the kidneys.
The game-changer for complement-mediated HUS has been eculizumab, a drug that blocks complement component C5 and halts the destructive cascade. Before complement-blocking therapy was available, outcomes were poor: many patients progressed to kidney failure or died. The introduction of complement inhibitors has fundamentally shifted prognosis, though patients typically need ongoing treatment because the underlying genetic predisposition does not go away.
Disseminated Intravascular Coagulation
DIC is a common and frequently overlooked cause of MAHA. Unlike TTP or HUS, DIC is not a primary disease of the blood vessels. It is triggered by something else, such as severe infection (sepsis), trauma, obstetric emergencies, or advanced cancer, and it throws the entire clotting system into chaos. The body simultaneously forms clots everywhere and bleeds everywhere because it exhausts its supply of clotting factors and platelets. The microangiopathic hemolysis in DIC comes from the same mechanism as in other TMAs: red cells shearing against fibrin strands in small vessels. But the clotting panel looks very different. Fibrinogen is low, prothrombin time and activated partial thromboplastin time are prolonged, and D-dimer levels are extremely high. Treating DIC means treating whatever triggered it, not plasma exchange.
Cancer as a Cause
MAHA can be a paraneoplastic syndrome, meaning the cancer itself is driving the blood destruction rather than any treatment. Cancer-related MAHA most often appears with disseminated solid tumors, especially gastric and breast cancers, where tumor cells seed the microvasculature and trigger clotting within capillaries.13Medicine. Cancer-Related Microangiopathic Hemolytic Anemia: Clinical and Laboratory Features in 168 Reported Cases It can also arise as a complication of cancer treatment, particularly with certain chemotherapy agents.14PubMed Central. Cancer-associated thrombotic microangiopathy
ADAMTS13 activity in cancer-associated MAHA is typically normal or only modestly reduced, well above the severely deficient levels seen in TTP.15PubMed Central. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura That distinction matters clinically because plasma exchange, the cornerstone of TTP treatment, does not help cancer-driven MAHA. Addressing the underlying malignancy is the only effective approach.
Drug-Induced and Transplant-Related MAHA
A growing list of medications can trigger TMA and therefore MAHA. Calcineurin inhibitors (tacrolimus, cyclosporine), certain chemotherapy drugs (gemcitabine, mitomycin C), VEGF pathway inhibitors used in cancer therapy, and even some antiplatelet agents have been implicated. The mechanisms vary: some drugs directly damage endothelial cells, others trigger immune-mediated injury, and some provoke complement activation. A thorough medication review is essential whenever MAHA is found without an obvious cause.
Stem cell transplant recipients face their own elevated risk. Post-transplant TMA has a multifactorial origin, involving the effects of immunosuppressive drugs, viral reactivation, radiation conditioning, and graft-versus-host disease all converging on the fragile endothelium.16PubMed Central. Post-bone marrow transplant thrombotic microangiopathy Diagnosis can be tricky because many of the lab features of TMA overlap with findings from the transplant process itself.
Autoimmune Disease and Scleroderma Renal Crisis
Systemic lupus erythematosus and antiphospholipid syndrome can both trigger secondary TMA with MAHA. In lupus, complement activation appears to play a central role, and complement-blocking therapy has been explored as an intervention.17PubMed Central. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature Distinguishing lupus-driven TMA from a concurrent TTP flare requires ADAMTS13 testing, because the two conditions can look nearly identical on routine labs.
Scleroderma renal crisis is another autoimmune emergency that produces MAHA. In scleroderma, progressive fibrosis and vascular injury can abruptly tip into a TMA pattern with severe hypertension, rapidly worsening kidney function, and schistocytes on the smear.18PubMed Central. Scleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy ACE inhibitors are the treatment of choice and can reverse the crisis if started early, making rapid recognition critical.
What the Kidney Biopsy Shows
When the cause of MAHA is not clear from bloodwork alone, a kidney biopsy can offer definitive evidence. In the acute phase of TMA, pathologists see swollen endothelial cells, fibrin deposits in glomerular capillaries, and fragmented red cells trapped in the vessel walls. In chronic or recurring disease, the vessels remodel: capillary walls develop a double-layered appearance from new basement membrane forming beneath the damaged endothelium, and arteries develop concentric “onion skin” thickening from smooth muscle cell buildup.19American Journal of Kidney Diseases. Thrombotic Microangiopathy: Core Curriculum 2023 Certain biopsy patterns can even point to specific causes. A distinctive pattern of dense material buildup under the endothelium has been linked specifically to VEGF-blocking cancer drugs.20American Journal of Kidney Diseases. Thrombotic Microangiopathy: Core Curriculum 2023
Long-Term Outcomes After an Episode
Surviving the acute crisis does not always mean the story is over. People who have recovered from TMA appear to carry an elevated risk of long-term vascular complications, including high blood pressure, kidney disease, stroke, seizures, and cognitive impairment. Across multiple studies, neurocognitive function and quality of life after TMA were found to be lower than in the general population.21PubMed. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review The exact magnitude of these risks remains unclear, and there is no established protocol for how closely to follow these patients after discharge.
For transplant recipients specifically, a history of TMA roughly tripled the odds of developing chronic kidney disease over the five years following transplant.22PubMed. Thrombotic Microangiopathy Increases the Risk of Chronic Kidney Disease but Not Overall Mortality in Long-term Transplant Survivors That finding did not translate into higher overall mortality in the same study, suggesting that the kidney damage, while real, can often be managed without shortening life.
Rare Metabolic Causes in Children
Not every case of MAHA in a young child is caused by E. coli. Cobalamin C deficiency, a rare inherited defect in vitamin B12 metabolism, can produce TMA that mimics other forms of HUS. Kidney biopsies in these patients show a characteristic pattern of clotting injury in the glomeruli and small arteries, with distinctive changes to the glomerular basement membrane that pathologists can distinguish from other causes of TMA.23PubMed Central. Cobalamin C Deficiency Induces a Typical Histopathological Pattern of Renal Arteriolar and Glomerular Thrombotic Microangiopathy The treatment is straightforward once the diagnosis is made: hydroxocobalamin (a form of B12) supplementation can halt the microangiopathy. The challenge is thinking of it in the first place, especially in infants presenting with kidney failure and MAHA where the reflexive assumption is infection-driven HUS.
Where Complement-Blocking Drugs Fit and Where They Do Not
The success of eculizumab in complement-mediated HUS led to widespread interest in using complement inhibitors for other forms of TMA. The reality is more nuanced. In TTP, there is some laboratory and animal evidence that the complement system is activated, but clinical studies looking at complement gene mutations in TTP patients came up empty, and complement blockade is not part of standard TTP management.24PubMed Central. C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea In lupus-associated TMA, the role of complement is more plausible, and case reports of eculizumab use have been published, but robust trial data are lacking. Post-transplant TMA occupies a gray zone: complement activation is sometimes a driver, sometimes not, and identifying which patients will respond requires specialized complement testing that is not universally available.
The lesson for patients and families is that “TMA” is not a single disease with a single treatment. Complement blockers are transformative for the right diagnosis and ineffective for the wrong one. Getting the right answer depends on careful integration of lab work, clinical context, genetic testing, and sometimes biopsy findings, which is why these cases are increasingly managed in consultation with hematologists who specialize in TMA.